These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34154827)

  • 21. Switching and Combining Device-Aided Therapies in Advanced Parkinson's Disease: A Double Centre Retrospective Study.
    Georgiev D; Delalić S; Zupančič Križnar N; Socher A; Gurevich T; Trošt M
    Brain Sci; 2022 Mar; 12(3):. PubMed ID: 35326299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson's disease on levodopa/carbidopa intestinal gel infusion.
    Garrì F; Russo FP; Carrer T; Weis L; Pistonesi F; Mainardi M; Sandre M; Savarino E; Farinati F; Del Sorbo F; Soliveri P; Calandrella D; Biundo R; Carecchio M; Zecchinelli AL; Pezzoli G; Antonini A
    J Neurol; 2022 Oct; 269(10):5606-5614. PubMed ID: 35876875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
    Nyholm D; Odin P; Johansson A; Chatamra K; Locke C; Dutta S; Othman AA
    AAPS J; 2013 Apr; 15(2):316-23. PubMed ID: 23229334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concomitant Medication Usage with Levodopa-Carbidopa Intestinal Gel: Results from the COSMOS Study.
    Fasano A; Gurevich T; Jech R; Kovács N; Svenningsson P; Szász J; Parra JC; Bergmann L; Johnson A; Sanchez-Soliño O; Tang Z; Vela-Desojo L
    Mov Disord; 2021 Aug; 36(8):1853-1862. PubMed ID: 33908647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proposition of zinc supplementation during levodopa-carbidopa intestinal gel treatment.
    Matsuyama H; Matsuura K; Ishikawa H; Hirata Y; Kato N; Niwa A; Narita Y; Tomimoto H
    Brain Behav; 2018 Dec; 8(12):e01143. PubMed ID: 30358126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations.
    Balestrino R; Martone T; Toffoli M; Montanaro E; Fabbri M; Artusi CA; Romagnolo A; Zibetti M; Rizzone M; Goldwurm S; Lopiano L; Schapira AHV
    Neurol Sci; 2024 Apr; 45(4):1489-1497. PubMed ID: 37926749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
    Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
    J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Motor and nonmotor symptoms in patients treated with 24-hour daily levodopa-carbidopa intestinal gel infusion: Analysis of the COmedication Study assessing Mono- and cOmbination therapy with levodopa-carbidopa inteStinal gel (COSMOS).
    Kovács N; Szász J; Vela-Desojo L; Svenningsson P; Femia S; Parra JC; Sanchez-Soliño O; Bergmann L; Gurevich T; Fasano A
    Parkinsonism Relat Disord; 2022 Dec; 105():139-144. PubMed ID: 36008198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients.
    Sücüllü Karadağ Y; Saltoğlu T; Erdoğan Küçükdağli F; Öztürk Ö; Köseoğlu HT; Altiparmak E
    Turk J Med Sci; 2021 Feb; 51(1):84-89. PubMed ID: 32718129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
    Wirdefeldt K; Odin P; Nyholm D
    CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.
    Buhmann C; Hilker R; Lingor P; Schrader C; Schwarz J; Wolz M; Reichmann H
    J Neural Transm (Vienna); 2017 Aug; 124(8):1005-1013. PubMed ID: 28229223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets.
    Othman AA; Dutta S
    Br J Clin Pharmacol; 2014 Jul; 78(1):94-105. PubMed ID: 24433449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinson's Disease.
    Thaler A; Barer Y; Gross R; Cohen R; Bergmann L; Jalundhwala YJ; Giladi N; Chodick G; Shalev V; Gurevich T
    Adv Ther; 2022 May; 39(5):2009-2024. PubMed ID: 35247187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levodopa-carbidopa intrajejunal infusion in Parkinson's disease: untangling the role of age.
    Morgante F; Oppo V; Fabbri M; Olivola E; Sorbera C; De Micco R; Ielo GC; Colucci F; Bonvegna S; Novelli A; Modugno N; Sensi M; Zibetti M; Lopiano L; Tessitore A; Pilleri M; Cilia R; Elia AE; Eleopra R; Ricciardi L; Cossu G
    J Neurol; 2021 May; 268(5):1728-1737. PubMed ID: 33354739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
    Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.
    Chaudhuri KR; Pickard AS; Alobaidi A; Jalundhwala YJ; Kandukuri PL; Bao Y; Sus J; Jones G; Ridley C; Oddsdottir J; Najle-Rahim S; Madin-Warburton M; Xu W; Schrag A
    Pharmacoeconomics; 2022 May; 40(5):559-574. PubMed ID: 35307793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Solla P; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Zangaglia R; Bentivoglio A; Eleopra R; Gualberti G; Melzi G; Antonini A
    J Neurol; 2019 Sep; 266(9):2164-2176. PubMed ID: 31134377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Selection of the optimal device-aided therapy in Parkinson's disease].
    Kovács N; Aschermann Z; Juhász A; Harmat M; Pintér D; Janszky J
    Ideggyogy Sz; 2019 Jan; 72(1-2):5-11. PubMed ID: 30785241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levodopa-Carbidopa Intestinal Gel for Parkinson's Disease over 11 years: One Center's "Real-World" Experience.
    Vekhande C; Hamed M; Tremain G; Mah J; Shetty A; Lazarescu A; Suchowersky O
    Can J Neurol Sci; 2024 May; 51(3):379-386. PubMed ID: 37462070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.